Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
A doctor mentioned in a bearish research note on Amarin (AMRN_) published Tuesday by SummerStreet Research Partners says he was misquoted and did not tell an audience of primary care doctors that FDA wouldn't approve the company's prescription-grade fish oil Vascepa without further clinical data. Dr. Eliot Brinton, reached by phone in Salt Lake City where he practices medicine, confirmed he is the "Amarin insider" mentioned in the Summer Street report. The report, however, was inaccurate, he says.
Help employers find you! Check out all the jobs and post your resume.
A doctor mentioned in a bearish research note on Amarin (AMRN_) published Tuesday by SummerStreet Research Partners says he was misquoted and did not tell an audience of primary care doctors that FDA wouldn't approve the company's prescription-grade fish oil Vascepa without further clinical data. Dr. Eliot Brinton, reached by phone in Salt Lake City where he practices medicine, confirmed he is the "Amarin insider" mentioned in the Summer Street report. The report, however, was inaccurate, he says.
Help employers find you! Check out all the jobs and post your resume.
